Mersana Therapeutics (MRSN) director Alleva received 8,972 Stock Option (right to buy)

Insider transactions reported

Lawrence M Alleva (director at Mersana Therapeutics Inc., MRSN) reported that they received 8,972 Stock Option (right to buy) on Jul 1, 2024.

Reporting person

Alleva Lawrence M

Options and other derivatives

Holdings before and after

• Stock Option (right to buy): 0 to 8,972 direct

Footnotes from the filing

1. 1. This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as amended, in lieu of retainer fees of $14,750 for the quarter ended June 30, 2024.
2. 2. Fully vested as of the date of grant.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ